Eucrates Biomedical Acquisition Corp. (EUCR) Investment Research Dashboard
About Eucrates Biomedical Acquisition Corp. (EUCR) stock analysis
Get live EUCR stock price $10.04, comprehensive Eucrates Biomedical Acquisition Corp. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time EUCR stock data and investment insights.
Loading chart data...
Eucrates Biomedical Acquisition Corp. (EUCR) Overview
Eucrates Biomedical Acquisition Corp. (EUCR) is a publicly traded company in the Financial Services sector , specifically within the Shell Companies industry . As of the latest trading session, EUCR trades at $10.04 with a market capitalization of 42.23M . Over the past 52 weeks, EUCR has traded between $9.87 and $10.25 , with the current price positioned at approximately 45% of this range . Th...
Key Takeaways
- Operates in the Financial Services sector (Shell Companies)
- Market cap: 42.23M
- Current price: $10.04
- 52-week range: $9.87 - $10.25
- P/E ratio: 47.81
Investment Score
A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Eucrates Biomedical Acquisition Corp. currently lacks substantial business operations. Its primary objective is to execute a corporate transaction such as a merger, stock swap, asset purchase, equity acquisition, restructuring, or another comparable ...
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Financial Services sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 47.8)
✓ Lower volatility stock (Beta: -0.07) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Eucrates Biomedical Acquisition Corp. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Financial Services may affect company performance
- ⚠Past performance does not guarantee future results for Eucrates Biomedical Acquisition Corp.
- ⚠Investors should consider how Eucrates Biomedical Acquisition Corp. fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 47.8) requires strong growth to justify
Market Cap
42.23M
P/E Ratio (TTM)
47.81
Beta
-0.07
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare EUCR with peer companies:
- Price
- $11.21+4.28% (1D)
- Market cap
- 82.33M
- Price
- $12.00+0.00% (1D)
- Market cap
- 33.91M
- Price
- $0.12+0.00% (1D)
- Market cap
- 1.13M
- Price
- $10.35+0.00% (1D)
- Market cap
- 163.15M
- Price
- $11.62+0.00% (1D)
- Market cap
- 25.93M
- Price
- $20.00+0.00% (1D)
- Market cap
- 342.64M
- Price
- $10.53+0.00% (1D)
- Market cap
- 341.44M
- Price
- $13.29+0.00% (1D)
- Market cap
- 49.22M
- Price
- $10.49+0.00% (1D)
- Market cap
- 55.45M
- Price
- $5.00+0.00% (1D)
- Market cap
- 35.38M
- Price
- $12.00+0.00% (1D)
- Market cap
- 57.38M
- Price
- $11.37+0.00% (1D)
- Market cap
- 81.05M
- Price
- $0.01+0.00% (1D)
- Market cap
- 76.85M
- Price
- $10.65+0.00% (1D)
- Market cap
- 262.02M
- Price
- $3.15+0.00% (1D)
- Market cap
- 25.25M
About Financial Services Sector
The Financial Services sector includes companies that provide banking, insurance, investment, and other financial services to consumers and businesses.
Financial Services (1D)
85/100 ⭐⭐⭐⭐⭐
- Overall
- +0.3%
- NYSE
- +1.2%
- NASDAQ
- -0.6%
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Financial Services | +0.3% | +0.9% | +3.0% | 19.0 | 85/100⭐⭐⭐⭐⭐ |
| Healthcare | +0.2% | +1.0% | +4.1% | 23.5 | 84/100⭐⭐⭐⭐⭐ |
| Real Estate | +1.8% | +2.1% | -0.3% | 29.7 | 72/100⭐⭐⭐⭐⭐ |
| Communication Services | +0.7% | -2.5% | +2.8% | 21.8 | 62/100⭐⭐⭐⭐ |
| Basic Materials | +0.9% | +0.4% | -1.3% | 24.9 | 55/100⭐⭐⭐⭐ |
| Consumer Defensive | +0.8% | -0.0% | -0.9% | 28.7 | 53/100⭐⭐⭐ |
| Utilities | -0.7% | +2.0% | -1.3% | 25.2 | 52/100⭐⭐⭐ |
| Energy | -0.2% | +0.4% | -2.4% | 19.6 | 49/100⭐⭐⭐ |
| Consumer Cyclical | +0.3% | -3.1% | -2.8% | 43.3 | 14/100⭐ |
| Technology | -1.6% | -0.3% | -3.1% | 42.2 | 14/100⭐ |
| Industrials | -0.5% | -1.3% | -8.9% | 30.4 | 10/100⭐ |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-27.